State-of-the-Art, Non-Invasive Ultrasound Technology Identifies Patients with Advanced Chronic Liver Disease
Posted on 09 Mar 2022
An affordable, cost-effective tool uses ultrasound technology for screening liver health, improving liver health management at the point of care for primary care practices and reducing the flow of patients in secondary care centers.
Echosens (France, Paris) has launched FibroScan GO, a state-of-the-art, non-invasive solution for identifying patients with advanced chronic liver disease. FibroScan GO is a solution for quickly and easily assessing liver stiffness using LSM by VCTE and CAP for liver fibrosis and steatosis assessment and management among patients with, or suspected of having, liver fibrosis and cirrhosis.
Chronic liver disease is a public health crisis that affects 1.9 billion people worldwide and accounts for two million deaths per year. The main causes of chronic liver disease include nonalcoholic fatty liver disease (NAFLD) and its more severe form non-alcoholic steatohepatitis (NASH), alcohol and viral hepatitis. FibroScan GO is designed for use in a medical practice in order to provide liver stiffness measurement at 50 Hz shear wave frequency and liver ultrasonic attenuation (CAP) at 3.5 MHz ultrasound frequency. It enables operators to screen at-risk patients for early intervention and diagnosis, patient stratification and monitoring of disease progression.
FibroScan GO integrates instantly into an office-based practice with small footprint and connectivity, acting as smaller, mobile equipment for easy integration outside of secondary care. It offers enhanced clinical decision support with the Interpretation Guide and Scores by Echosens available on the myFibroScan app. It is integrated with Echosens Cloud for centralized and secure data management. The fast, simple and non-invasive examination can be performed by any trained operator, including healthcare practitioner or nurse. The test is repeatable and reproducible and offers consistent results.
“Primary care practices can now manage and monitor at-risk patients and make an early diagnosis, which is essential for halting or reversing liver disease,” said Dominique Legros, Group CEO, Echosens. “FibroScan GO is a powerful tool for the prognosis of disease course, enabling immediate medical decisions for improved patient outcomes and higher healthcare efficiency.”
“Echosens is bringing greater peace of mind with FibroScan GO’s proactive and dedicated support team who assist with onsite installation and training. With a flexible and affordable pay per exam offer, this tool not only reduces referrals to secondary care, but also obviates the need for capital investment to achieve an early liver disease diagnosis that reduces the cost of liver-related illness,” added Legros.
Related Links:
Echosens
